【摘要】 为探讨不同内皮型一氧化氮合酶 (eNOS)基因型 ( 4b/a)原发性高血压 (以下简称高血压 )病人对血管紧张素Ⅱ受体拮抗剂 (缬沙坦 )降压的反应性 ,将 72例高血压病人根据eNOS 4b/a基因多态性分为aa +ab组 ( 1 6例 )和bb组 ( 5 6例 ) ,均口服缬沙坦 4周 ,并测量血压。发现 :aa+ab组的降压总有效率为 93 .8% ,bb组总有效率为 64.3 % ;缬沙坦对aa+ab组的降压效果强于bb组。提示 :eNOS 4b/a基因多态性可作为高血压病人选用血管紧张素Ⅱ受体拮抗剂的参考指标之一更多还原

【Abstract】 To investigate the response of patients with different endothelial nitric oxide synthase(eNOS) genotype (4b/a)to the treatment of angiotensin Ⅱ type 1 receptor antagonist (valsartan), 72 patients with hypertension were divided into two groups according to eNOS gene 4b/a polymorphism: aa+ab group (n=16)and bb group (n=56). All patients were treated with valsartan for 4 weeks and their blood pressure were measured.Effective rate of valsartan antihypertension in aa+ab group was 93.8%, but the effective rate in bb group was 64.3%. Curative effects of valsartan was significantly higher in aa+ab group than in bb group. It is suggested that eNOS 4b/a gene polymorphism can be used as one of adjustive indicators for predicting the effects of using angiotensin Ⅱ type 1 receptor antagonist in treatment of hypertensive patients.更多还原